BYOOVIZ (ranibizumab-nuna)
BYOOVIZ is indicated for the treatment of Neovascular Age-Related Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Myopic Choroidal Neovascularization.
How BYOOVIZ Works
Ranibizumab-nuna functions by binding to the receptor binding site of active forms of vascular endothelial growth factor A (VEGF-A). By binding to this protein, the drug prevents VEGF-A from interacting with its receptors, VEGFR1 and VEGFR2, on the surface of endothelial cells. This inhibition reduces the proliferation of endothelial cells, decreases vascular leakage, and limits the formation of new blood vessels. These actions target the biological processes that contribute to neovascularization and edema in the retina.
Details
- Status
- Prescription
- First Approved
- 2021-09-17
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
BYOOVIZ Approval History
What BYOOVIZ Treats
4 indicationsBYOOVIZ is approved for 4 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Myopic Choroidal Neovascularization
BYOOVIZ Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
Pharmacists can substitute BYOOVIZ for Lucentis without calling the prescriber. This is a lower-cost alternative with no clinically meaningful differences.
BYOOVIZ Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to BYOOVIZ
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BYOOVIZ FDA Label Details
Indications & Usage
FDA Label (PDF)BYOOVIZ is indicated for the treatment of Neovascular Age-Related Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Myopic Choroidal Neovascularization.
Track BYOOVIZ with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.